FDA Guidance on Conduct of Clinical Trials of Medical Products During the Public Health Emergency

John Concato, MD, MS MPH, acting associate director of real-world evidence analytics in the Office of Medical Policy, discusses the creation of the FDA guidance “Conducting Clinical Trails of Medical Products During the COVID-19 Public Health Emergency and the opening of the Clinicaltrialconduct-COVID19@fda.hhs.gov mailbox; and their role in promoting the safety of trial participants, maintaining compliance with good clinical practice, and minimizing risks to trial integrity.

Learn More at: https://www.fda.gov/drugs/regulatory-education-industry-redi-annual-conference-2021-07192021-07232021

_______________________________ 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  
 
Upcoming Training – https://www.fda.gov/cdersbia
SBIA Listserv – https://public.govdelivery.com/accounts/USFDA/subscriber/new?topic_id=USFDA_352
SBIA 2021 Playlist – https://youtube.com/playlist?list=PLey4Qe-UxcxYS1MaTusSgyifQDqdeepyD
SBIA LinkedIn – https://www.linkedin.com/showcase/cder-small-business-and-industry-assistance
SBIA Training Resources – https://www.fda.gov/cdersbialearn
Twitter – https://twitter.com/FDA_Drug_Info
Email – CDERSBIA@fda.hhs.gov
Phone – (301) 796-6707 I (866) 405-5367